Evidence map›Paper›PMID 29178847›Full record

ArticleBMC infectious diseases2017

HIV serostatus knowledge and serostatus disclosure with the most recent anal intercourse partner in a European MSM sample recruited in 13 cities: results from the Sialon-II study.

Ulrich Marcus, Susanne Barbara Schink, Nigel Sherriff, Anna-Marie Jones, Lorenzo Gios, Cinta Folch, Torsten Berglund, Christiana Nöstlinger, Marta Niedźwiedzka-Stadnik, Sonia F Dias and 10 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Quantifying unmet prevention needs among MSM in Europe through a multi-site bio-behavioural survey.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 13 countries.

Ulrich MarcusDepartment of Infectious Diseases Epidemiology, Robert Koch-Institute, Berlin, Germany. MarcusU@rki.de.ORCID 0000-0002-3143-2717
Susanne Barbara SchinkDepartment of Infectious Diseases Epidemiology, Robert Koch-Institute, Berlin, Germany.
Nigel SherriffUniversity of Brighton, Health Sciences, Brighton, UK.
Anna-Marie JonesUniversity of Brighton, Health Sciences, Brighton, UK.
Lorenzo GiosDepartment of Health, Verona University Hospital, CReMPE - Regional Coordination Centre for European Project Management, Verona, Veneto Region, Italy.
Cinta FolchCentre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Agència de Salut Pública de Catalunya (ASPC), Badalona, Spain.
Torsten BerglundDepartment of Monitoring & Evaluation, Public Health Agency of Sweden, Solna, Sweden.
Christiana NöstlingerDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Marta Niedźwiedzka-StadnikDepartment of Epidemiology, National Institute of Public Health, Warsaw, Poland.
Sonia F DiasUniversidade Nova de Lisboa, Instituto de Higiene e Medicina Tropical, Global Health and Tropical Medicine, Lisbon, Portugal.
Ana F GamaUniversidade Nova de Lisboa, Instituto de Higiene e Medicina Tropical, Global Health and Tropical Medicine, Lisbon, Portugal.
Emilia NasevaMinistry of Health, Program "Prevention and Control of HIV/AIDS", Sofia, Bulgaria.
Ivailo AlexievNational Centre of Infectious and Parasitic Diseases, National Reference Laboratory of HIV, Sofia, Bulgaria.
Danica StanekováSlovak Medical University, National Reference Centre for HIV/AIDS, Bratislava, Slovakia.
Igor ToskinDepartment of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
Daniela PitigoiUniversity of Medicine and Pharmacy Carol Davila, Department Clinic 2, Epidemiology, Bucharest, Romania.
Alexandru RafilaDepartment of Microbiology, National Institute of Infectious Diseases "Prof Dr Matei Bals", Bucharest, Romania.
Irena KlavsNational Institute of Public Health, Communicable Diseases Centre, Ljubljana, Slovenia.
Massimo MirandolaDepartment of Health, Infectious Disease Section, Verona University Hospital, CReMPE - Regional Coordination Centre for European Project Management, Verona, Veneto Region, Italy.
Sialon II Network
University of Verona · ITRobert Koch Institute · DECarol Davila University of Medicine and Pharmacy · RONarodowy Instytut Zdrowia Publicznego PZH – Państwowy Instytut Badawczy · PLPublic Health Agency of Sweden · SESlovak Medical University · SKUniversidade Nova de Lisboa · PTMill View Hospital · GBNational Center of Infectious and Parasitic Diseases · BGNational Institute of Research and Development for Biological Sciences · RO

Funding

Consumers, Health, Agriculture and Food Executive Agency 100880World Health Organization 001
6 · The paper itself

Abstract

backgroundKnowledge of HIV status can be important in reducing the risk of HIV exposure. In a European sample of men-who-have-sex-with-men (MSM), we aimed to identify factors associated with HIV serostatus disclosure to the most recent anal intercourse (AI) partner. We also aimed to describe the impact of HIV serostatus disclosure on HIV exposure risks.

methodsDuring 2013 and 2014, 4901 participants were recruited for the bio-behavioural Sialon-II study in 13 European cities. Behavioural data were collected with a self-administered paper questionnaire. Biological specimens were tested for HIV antibodies. Factors associated with HIV serostatus disclosure with the most recent AI partner were examined using bivariate and multilevel multivariate logistic regression analysis. We also describe the role of serostatus disclosure for HIV exposure of the most recent AI partner.

resultsThirty-five percent (n = 1450) of the study participants reported mutual serostatus disclosure with their most recent AI partner or disclosed having HIV to their partner. Most of these disclosures occurred between steady partners (74%, n = 1077). In addition to the type of partner and HIV diagnosis status, other factors positively associated with HIV serostatus disclosure in the multilevel multivariate logistic regression model were recent testing, no condom use, and outness regarding sexual orientation. Disclosure rates were lowest in three south-eastern European cities. Following condom use (51%, n = 2099), HIV serostatus disclosure (20%, n = 807) was the second most common prevention approach with the most recent AI partner, usually resulting in serosorting. A potential HIV exposure risk for the partner was reported by 26% (111/432) of HIV antibody positive study participants. In 18% (20/111) of exposure episodes, an incorrect HIV serostatus was unknowingly communicated. Partner exposures were equally distributed between steady and non-steady partners.

conclusionsThe probability of HIV exposure through condomless AI is substantially lower after serostatus disclosure compared to non-disclosure. Incorrect knowledge of one's HIV status contributes to a large proportion of HIV exposures amongst European MSM. Maintaining or improving condom use for anal intercourse with non-steady partners, frequent testing to update HIV serostatus awareness, and increased serostatus disclosure particularly between steady partners are confirmed as key aspects for reducing HIV exposures amongst European MSM.

Indexed as

HIV InfectionsHIV SeropositivityAdultCitiesDisclosureEuropeHIV AntibodiesHomosexuality, MaleHumansLogistic ModelsMaleMiddle AgedSafe SexSexual BehaviorSexual PartnersSurveys and QuestionnairesHIV AntibodiesBio-behavioural surveyHIV exposureHIV serostatus disclosureMen who have sex with men

Identifiers

PMID29178847
PMCPMC5702243
OpenAlexW2769790081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.